524414 NORRIS

Norris Medicines Share Price

 

 

Start SIP in NORRIS

Start SIP

Performance

  • Low
  • ₹15
  • High
  • ₹15
  • 52 Week Low
  • ₹14
  • 52 Week High
  • ₹25
  • Open Price₹15
  • Previous Close₹15
  • Volume500

Investment Returns

  • Over 1 Month -9.52%
  • Over 3 Month -6.75%
  • Over 6 Month -26.63%
  • Over 1 Year -35.09%

Smart Investing Starts Here Start SIP with Norris Medicines for Steady Growth!

Invest Now

Norris Medicines Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -9.7
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 15
  • P/B Ratio
  • Average True Range
  • 1
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.31
  • RSI
  • 46.36
  • MFI
  • 36.49

Norris Medicines Financials

Norris Medicines Technicals

EMA & SMA

Current Price
₹14.93
-0.07 (-0.47%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹15.27
  • 50 Day
  • ₹15.78
  • 100 Day
  • ₹16.34
  • 200 Day
  • ₹16.93

Resistance and Support

14.88 Pivot Speed
  • R3 16.97
  • R2 16.23
  • R1 15.62
  • S1 14.27
  • S2 13.53
  • S3 12.92

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Norris Medicines has an operating revenue of Rs. 7.28 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of -20% needs improvement, NULL From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 29 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Norris Medicines Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-08-14 Quarterly Results
2025-05-28 Audited Results
2025-02-13 Quarterly Results & Others Inter-alia, to consider 1. Requests from Mr. Nimish Bhishma Thakore, for reclassification from Promoter / Promoter Group into Public Category. 2. Other business matters.
2024-11-14 Quarterly Results

Norris Medicines F&O

Norris Medicines Shareholding Pattern

34%
0.01%
0.06%
20.78%
45.15%

Norris Medicines FAQs

Norris Medicines share price is ₹14 As on 09 December, 2025 | 10:12

The Market Cap of Norris Medicines is ₹14.9 Cr As on 09 December, 2025 | 10:12

The P/E ratio of Norris Medicines is -9.7 As on 09 December, 2025 | 10:12

The PB ratio of Norris Medicines is -1 As on 09 December, 2025 | 10:12

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23